KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash from Financing Activities: 2009-2025

Historic Cash from Financing Activities for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $4.3 million.

  • Rigel Pharmaceuticals' Cash from Financing Activities rose 143.40% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 152.60%. This contributed to the annual value of -$11.6 million for FY2024, which is 163.38% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Cash from Financing Activities stood at $4.3 million, which was up 921.77% from $418,000 recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Cash from Financing Activities peaked at $59.2 million during Q2 2021, and registered a low of -$9.8 million during Q3 2024.
  • Over the past 3 years, Rigel Pharmaceuticals' median Cash from Financing Activities value was $418,000 (recorded in 2025), while the average stood at $1.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 1,911.31% in 2022, then tumbled by 1,032.57% in 2024.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2021, then crashed by 293.18% to -$2.1 million in 2022, then soared by 123.19% to $486,000 in 2023, then spiked by 201.44% to $1.5 million in 2024, then spiked by 143.40% to $4.3 million in 2025.
  • Its Cash from Financing Activities was $4.3 million in Q3 2025, compared to $418,000 in Q2 2025 and $484,000 in Q1 2025.